Stylus will use the Eli Lilly and J&J-backed funds to advance its in vivo genetic medicines platform and develop its pipeline ...

Cambridge, USA-based biotech Stylus Medicine, which says it is dedicated to developing transformative in vivo genetic ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

Stylus Medicine, a startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes ...

Stylus Medicine Inc., a biotechnology company dedicated to developing transformative in vivo genetic medicines, has emerged ...

Stylus Medicine is developing transformative in vivo genetic medicines to unlock cures. Stylus combines engineered recombinases with non-viral delivery to specifically encode therapeutics.

Industry layoffs continue to accelerate, this time hitting RA Capital’s biotech incubator, according to Stat News ...